Coordinated Transcriptional and Catabolic Programs Support Iron Dependent Adaptation to RAS-MAPK Pathway Inhibition in Pancreatic Cancer

Using transcriptome and chromatin immunoprecipitation profiling of PDA cells treated with the MEK inhibitor, Trametinib (MEKi), researchers identified transcriptional antagonism between c-MYC and the master transcription factors for lysosome gene expression, the MiT/TFE proteins.